ID: h-c27bd44a
Hypothesis
Cathepsin D Replacement to Overcome Lysosomal Protease Deficiency
Cathepsin D Replacement to Overcome Lysosomal Protease Deficiency.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 6 oppose
🧪 Overview
Cathepsin D Replacement to Overcome Lysosomal Protease Deficiency
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Cathepsin D<br/>Protease Deficiency"]
B["Lysosomal<br/>Proteolysis Impairment"]
C["Accumulated<br/>Substrate Proteins"]
D["Proteostasis<br/>Failure"]
E["Exogenous Cathepsin D<br/>Replacement"]
F["Lysosomal<br/>Function Restoration"]
G["Proteostatic<br/>Recovery"]
A --> B
B --> C
C --> D
E --> F
F --> G
G --> D
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports6 contradicts
Supports
Cathepsin D deficiency causes severe neurodegeneration with lysosomal storage accumulation
Supports
Cathepsin D expression and activity are reduced in aged brain and AD temporal lobe
Supports
Lysosomal pH becomes less acidic in aging neurons, impairing cathepsin activation
Supports
Cystamine/cysteamine increases cathepsin D activity and reduces aggregation in NCL models
Supports
Cathepsin D is major aspartic protease responsible for degrading protein aggregates in lysosomes
Contradicts
Cathepsin D knockout mice paradoxically have enhanced Aβ deposition due to compensatory protease upregulation
Contradicts
Cathepsin D processes neurotrophins (BDNF, NGF) - disruption may impair signaling
Contradicts
AAV delivery to aged neurons inefficient due to impaired trafficking - defeats strategy
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CTSD
No curated PDB or AlphaFold mapping for CTSD yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CTSD (cathepsin D) from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CTSD (cathepsin D).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.7%
Volatility
Low
0.0171
Events (7d)
3
Price History
▲6.2%💾 Resource Usage
LLM Tokens
39,448
$0.1183
Total Cost
$0.1183
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF cultured CTSD-deficient patient-derived fibroblasts are treated with exogenous recombinant human cathepsin D enzyme (50 μg/mL, 72 hours), THEN intracellular lysosomal autofluorescence (lipofuscin a | ≥40% reduction in lysosomal autofluorescence intensity and restoration of cathepsin D activity to ≥25% of normal levels | — no observation — | pending | 0.00 |
| IF CTSD-knockout mice (Ctsd−/−) receive AAV9-mediated CTSD gene delivery via intracerebroventricular injection (1×10^10 vg, single dose), THEN brain tissue harvested at 4 weeks post-injection will sho | Restoration of brain lysosomal protease activity to ≥30% of heterozygous control levels and ≥25% reduction in cortical autofluorescence at 4 weeks | — no observation — | pending | 0.00 |
🔮 Falsifiable Predictions (2)
pendingconf 0%
IF cultured CTSD-deficient patient-derived fibroblasts are treated with exogenous recombinant human cathepsin D enzyme (50 μg/mL, 72 hours), THEN intracellular lysosomal autofluorescence (lipofuscin accumulation) will decrease by ≥40% relative to vehicle-treated deficient cells, and cathepsin D enzy
Predicted outcome: ≥40% reduction in lysosomal autofluorescence intensity and restoration of cathepsin D activity to ≥25% of normal levels
Falsification: No significant reduction in autofluorescence or substrate accumulation markers (p62/SQSTM1, LC3-II); cathepsin D activity remains below 10% of wild-type despite treatment
pendingconf 0%
IF CTSD-knockout mice (Ctsd−/−) receive AAV9-mediated CTSD gene delivery via intracerebroventricular injection (1×10^10 vg, single dose), THEN brain tissue harvested at 4 weeks post-injection will show restored lysosomal proteolytic activity (measured by DQ-BSA assay) to ≥30% of heterozygous Ctsd+/−
Predicted outcome: Restoration of brain lysosomal protease activity to ≥30% of heterozygous control levels and ≥25% reduction in cortical autofluorescence at 4 weeks
Falsification: Ctsd expression undetectable by qPCR/western blot in brain tissue; no improvement in lysosomal protease activity; lipopigment burden unchanged or increased relative to untreated knockout mice
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.